The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM).
Mimi I-Nan Hu
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Ilya Glezerman
Research Funding - Amgen
Sophie Leboulleux
No relevant relationships to disclose
Karl L. Insogna
Research Funding - Amgen
Rasim A. Gucalp
No relevant relationships to disclose
Waldemar Misiorowski
No relevant relationships to disclose
Bennett Winston Yu
No relevant relationships to disclose
Paul Zorsky
No relevant relationships to disclose
Diego Tosi
No relevant relationships to disclose
Alberto Bessudo
No relevant relationships to disclose
Arnaud Jaccard
No relevant relationships to disclose
Giuseppe Tonini
No relevant relationships to disclose
Huei Wang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ada Braun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Rajul K. Jain
Employment or Leadership Position - Amgen
Stock Ownership - Amgen